The acetylation status of histones is regulated in eukaryotes by two kinds of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs), which are responsible for acetylation and deacetylation of lysines residues in N-terminal tails of histone.[1] Thus acetylation, together with phosphorylation and methylation of N-terminal tail of histones, are involved in regulating fundamental processes, such as proliferation and cell death.[2-3] Sodium butyrate, which belongs together with valproic acid to the class of short chain fatty acids, was the first HDAC inhibitor (HDACI) to be identified.[1] Organotin compounds have various influences on physical function including the hormone and immune systems, embryogenesis, and development. Dibutyltin and diphenyltin, metabolites of TBT and TPT, respectively, also promoted HAT activity.[4] New triorganotin(IV) complexes of valproic acid have been synthesized and investigated by spectroscopical and biological methods. An anionic, monodentate valproate ligand was observed, ester-like coordinating the tin atom on a tetra-coordinated, monomeric environment. The structures, though, can distort towards a pentacoordination, as a consequence of a long range O-Sn interaction. Crystallographic and NMR findings confirm this situation both in solid state and solution. Biological finding evidenced a clear cytotoxic action of the complexes in hepatocellular carcinoma cell cultures: one of the complexes induced an 80% cell viability reduction after 24 h treatment in HepG2 cells. This effect was accompanied by the appearance of biochemical signs of apoptosis. In Chang liver cells, the same compound induced only modest effects, suggesting a potential use as anti-cancer drug.

Pellerito C, Prinzivalli C, Foresti E, Sabatino P, Abbate M, Casella G, et al. (2011). New histone acetylation/deacetylation specific inhibitors: a novel and potential approach to cancer therapy. In 11th Workshop on PharmacoBioMetallics (pp.39-39). Camerino.

New histone acetylation/deacetylation specific inhibitors: a novel and potential approach to cancer therapy

PELLERITO, Claudia;ABBATE, Michele;CASELLA, Girolamo;FIORE, Tiziana;SCOPELLITI, Michelangelo;PELLERITO, Ornella;GIULIANO, Michela;PELLERITO, Lorenzo
2011-01-01

Abstract

The acetylation status of histones is regulated in eukaryotes by two kinds of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs), which are responsible for acetylation and deacetylation of lysines residues in N-terminal tails of histone.[1] Thus acetylation, together with phosphorylation and methylation of N-terminal tail of histones, are involved in regulating fundamental processes, such as proliferation and cell death.[2-3] Sodium butyrate, which belongs together with valproic acid to the class of short chain fatty acids, was the first HDAC inhibitor (HDACI) to be identified.[1] Organotin compounds have various influences on physical function including the hormone and immune systems, embryogenesis, and development. Dibutyltin and diphenyltin, metabolites of TBT and TPT, respectively, also promoted HAT activity.[4] New triorganotin(IV) complexes of valproic acid have been synthesized and investigated by spectroscopical and biological methods. An anionic, monodentate valproate ligand was observed, ester-like coordinating the tin atom on a tetra-coordinated, monomeric environment. The structures, though, can distort towards a pentacoordination, as a consequence of a long range O-Sn interaction. Crystallographic and NMR findings confirm this situation both in solid state and solution. Biological finding evidenced a clear cytotoxic action of the complexes in hepatocellular carcinoma cell cultures: one of the complexes induced an 80% cell viability reduction after 24 h treatment in HepG2 cells. This effect was accompanied by the appearance of biochemical signs of apoptosis. In Chang liver cells, the same compound induced only modest effects, suggesting a potential use as anti-cancer drug.
29-ott-2011
11th Workshop on PharmacoBioMetallics
San Benedetto del Tronto (AP)
28-30 ottobre 2011
2011
1
A stampa
Pellerito C, Prinzivalli C, Foresti E, Sabatino P, Abbate M, Casella G, et al. (2011). New histone acetylation/deacetylation specific inhibitors: a novel and potential approach to cancer therapy. In 11th Workshop on PharmacoBioMetallics (pp.39-39). Camerino.
Proceedings (atti dei congressi)
Pellerito C; Prinzivalli C; Foresti E; Sabatino P; Abbate M; Casella G; Fiore T; Scopelliti M; Pellerito O; Giuliano M; Grasso G; Pellerito L
File in questo prodotto:
File Dimensione Formato  
claudia2.pdf

Solo gestori archvio

Dimensione 97.83 kB
Formato Adobe PDF
97.83 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/61249
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact